Extended DaraKRd: Are we enhancing outcomes by prolonging treatment?
作者信息
Schmidt Timothy M
机构信息
University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
出版信息
Blood Cancer J. 2024 Jun 4;14(1):93. doi: 10.1038/s41408-024-01070-2.
Abstract
摘要
相似文献
1
Extended DaraKRd: Are we enhancing outcomes by prolonging treatment?延长疗程的达雷妥尤单抗联合来那度胺及地塞米松方案：我们通过延长治疗来改善疗效吗？
Blood Cancer J. 2024 Jun 4;14(1):93. doi: 10.1038/s41408-024-01070-2.
2
Defining futile life-prolonging treatments through Neo-Socratic Dialogue.通过新苏克拉底式对话来定义无益的延长生命的治疗。
BMC Med Ethics. 2013 Dec 9;14:51. doi: 10.1186/1472-6939-14-51.
3
How long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments.持续时间和效果如何：肿瘤学家对延长生命和提高生活质量治疗的相对价值的态度。
Med Decis Making. 2011 May-Jun;31(3):380-5. doi: 10.1177/0272989X10385847. Epub 2010 Nov 18.
4
Facing life-prolonging treatment: The perspectives of men with advanced metastatic prostate cancer - An interview study.面对延长生命的治疗：晚期转移性前列腺癌男性患者的观点 - 一项访谈研究。
Eur J Oncol Nurs. 2020 Dec;49:101859. doi: 10.1016/j.ejon.2020.101859. Epub 2020 Oct 16.
5
Experiences of caregivers desiring to refuse life-prolonging treatment for their elderly parents at the end of life.照顾者在老年人生命末期希望拒绝为其父母进行延长生命治疗的经历。
Int J Qual Stud Health Well-being. 2019 Dec;14(1):1632110. doi: 10.1080/17482631.2019.1632110.
6
Changes in End-of-Life Practices in European Intensive Care Units From 1999 to 2016.1999年至2016年欧洲重症监护病房临终护理实践的变化
JAMA. 2019 Nov 5;322(17):1692-1704. doi: 10.1001/jama.2019.14608.
7
Prescription and Dispensation of QT-Prolonging Medications in Individuals Receiving Hemodialysis.接受血液透析个体的 QT 延长药物的处方与调配。
JAMA Netw Open. 2024 Apr 1;7(4):e248732. doi: 10.1001/jamanetworkopen.2024.8732.
8
Association between subjective economic status and refusal of life-prolonging treatment: a cross-sectional study using content analysis with stratified random sampling.主观经济地位与拒绝延长生命治疗的关联：一项使用分层随机抽样内容分析法的横断面研究。
Fukushima J Med Sci. 2022 Apr 8;68(1):11-18. doi: 10.5387/fms.2021-13. Epub 2022 Jan 20.
9
High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units.在冠心病监护病房中，QT 间期延长的风险因素和相关药物相互作用的流行率很高。
Postgrad Med. 2018 Nov;130(8):660-665. doi: 10.1080/00325481.2018.1516106. Epub 2018 Sep 5.
10
Frequency of high-risk use of QT-prolonging medications.延长QT间期药物的高风险使用频率。
Pharmacoepidemiol Drug Saf. 2006 Jun;15(6):361-8. doi: 10.1002/pds.1155.
本文引用的文献
1
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.新诊断多发性骨髓瘤患者未经移植的达雷妥尤单抗、卡非佐米、来那度胺和地塞米松的 II 期试验的最终分析。
Blood Cancer J. 2024 May 29;14(1):87. doi: 10.1038/s41408-024-01045-3.
2
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.伊沙佐米、卡非佐米、来那度胺和地塞米松治疗新诊断、适合移植的多发性骨髓瘤患者（SKylaRk）：一项单臂、2 期临床试验。
Lancet Haematol. 2024 Jun;11(6):e415-e424. doi: 10.1016/S2352-3026(24)00070-X. Epub 2024 Apr 24.
3
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma.达雷妥尤单抗、卡非佐米、来那度胺和地塞米松联合双次移植治疗高危初诊多发性骨髓瘤。
Blood. 2024 May 16;143(20):2029-2036. doi: 10.1182/blood.2023023597.
4
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
5
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.新诊断多发性骨髓瘤（MASTER）中基于微小残留病灶反应的适应性治疗：多中心、单臂、2 期试验的最终报告。
Lancet Haematol. 2023 Nov;10(11):e890-e901. doi: 10.1016/S2352-3026(23)00236-3. Epub 2023 Sep 27.
6
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.伊沙佐米、卡非佐米、来那度胺和地塞米松治疗高危初诊多发性骨髓瘤。
J Clin Oncol. 2024 Jan 1;42(1):26-37. doi: 10.1200/JCO.23.01696. Epub 2023 Sep 27.
7
Potential future direction of measurable residual disease evaluation in multiple myeloma.多发性骨髓瘤中可测量残留病灶评估的潜在未来方向。
Blood. 2023 Nov 2;142(18):1509-1517. doi: 10.1182/blood.2023020284.
8
Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapy.在四联疗法时代多发性骨髓瘤中微小残留病灶评估的临床意义。
Leuk Lymphoma. 2022 Dec;63(14):3288-3298. doi: 10.1080/10428194.2022.2123231. Epub 2022 Sep 28.
9
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.达雷妥尤单抗联合来那度胺和地塞米松治疗不适合移植的新诊断多发性骨髓瘤：MAIA 研究脆弱亚组分析。
Leukemia. 2022 Apr;36(4):1066-1077. doi: 10.1038/s41375-021-01488-8. Epub 2022 Jan 2.
10
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.每周卡非佐米、来那度胺、地塞米松和达雷妥尤单抗联合治疗新诊断多发性骨髓瘤患者的安全性和有效性：MANHATTAN 非随机临床试验。
JAMA Oncol. 2021 Jun 1;7(6):862-868. doi: 10.1001/jamaoncol.2021.0611.
Zotero 插件